Karyopharm Therapeutics Inc (NASDAQ:KPTI) saw a downside of -8.00% to close Friday at $1.15 after subtracting -$0.1 on the day. The 5-day average trading volume is 1,085,360 shares of the company’s common stock. It has gained $1.2600 in the past week and touched a new high 3 times within the past 5 days. An average of 1,245,240 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,306,566.
KPTI’s 1-month performance is -21.23% or -$0.3200 on its low of $1.1100 reached on 09/18/23. The company’s shares have touched a 52-week low of $1.11 and high of $6.01, with the stock’s rally to the 52-week high happening on 04/17/23. YTD, KPTI has lost -66.18% or -$2.2500 and has reached a new high 13 times. However, the current price is down -80.87% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
KPTI stock investors last saw insider trading activity on Sep 12.Paulson Richard A. (President and CEO) most recently sold 3,622 shares at $1.33 per share on Sep 05. This transaction cost the insider $4,817. EVP & Chief Commercial Officer, Cheng Sohanya Roshan, sold 7,415 shares at a price of $1.33 on Sep 01. Then, on Sep 01, EVP, CFO & Treasurer Mason Michael sold 6,913 shares at a price of $1.33 per share. This transaction amounted to $9,203.
Valuation Metrics
KPTI stock has a beta of -0.02. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.90.
Karyopharm Therapeutics Inc’s quick ratio for the period ended June 29 was 4.88, with the current ratio over the same period at 4.94. In terms of profitability, the gross margin trailing 12 months is 95.85%. The trailing 12-month EBITDA margin is -90.14% while for the period ending June 29, Karyopharm Therapeutics Inc’s operating margin was -85.74%. The firm’s gross profit as reported stood at $151.86 million against revenue of $157.07 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -50.35% to -$32.63 million, while revenue of -$34.13 million was -4.6% off the previous quarter. Analysts expected KPTI to announce -$0.34 per share in earnings in its latest quarter, but it posted -$0.29, representing a 14.70% surprise. EBITDA for the quarter stood at more than -$30.31 million. KPTI stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 369.08 million, with total debt at $310.8 million. Shareholders hold equity totaling $114.36 million.
Let’s look briefly at Karyopharm Therapeutics Inc (KPTI) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 36.98% to suggest the stock is trending Neutral, with historical volatility in this time period at 79.96%.
The stock’s 5-day moving average is $1.1840, reflecting a -4.96% or -$0.0600 change from its current price. KPTI is currently trading -17.27% above its 20-day SMA, -70.13% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -29.88% and SMA200 by-78.01%.
Stochastic %K and %D was 28.84% and 27.19% and the average true range (ATR) pointed at 0.1071. The RSI (14) points at 36.63%, while the 14-day stochastic is at 14.81% with the period’s ATR at 0.1105. The stock’s 9-day MACD Oscillator is pointing at -0.0256 and -0.0169 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Karyopharm Therapeutics Inc (NASDAQ: KPTI), Piper Sandler launched coverage with an Overweight rating. Analysts offering their rating for KPTI stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate KPTI as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 4 have offered a “buy” rating.
What is KPTI’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $10.00, with their median price target at $6.00. Looking at these predictions, the average price target given by analysts is for Karyopharm Therapeutics Inc (KPTI) stock is $6.50.
